{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:51:03Z","timestamp":1758905463855},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1097\/01.ju.0000108860.03389.1b","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T22:53:02Z","timestamp":1093474382000},"page":"1688-1697","source":"Crossref","is-referenced-by-count":24,"title":["SENSITIVITY OF RENAL CELL CARCINOMA TO AMINOFLAVONE: ROLE OF CYP1A1"],"prefix":"10.1097","volume":"171","author":[{"given":"A.I.","family":"LOAIZA-P\u00c9REZ","sequence":"first","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"KENNEY","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"BOSWELL","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"HOLLINGSHEAD","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"HOSE","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.M.","family":"LINEHAN","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"WORRELL","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"RUBINSTEIN","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"SAUSVILLE","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.T.","family":"VISTICA","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (AIL-P, EAS), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (LR) and Urologic Oncology Branch (ML, RW), National Cancer Institute, National Institutes of Health, Bethesda and Screening Technologies (SK, DTV) and Biological Testing (MH) Branches, National Cancer Institute and Basic Research Program, SAIC-Frederick, Inc. (JB, CH), National Cancer Institute Frederick, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1097\/01.ju.0000108860.03389.1b_bib1","series-title":"Advances in Experimental Medicine and Biology 505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4757-5235-9_1","article-title":"Flavonoids and cell function","author":"Manthey","year":"2002"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.aje.a009257","article-title":"Dietary flavonoids and the risk of lung cancer and other malignant neoplasms","volume":"146","author":"Knekt","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/jnci\/92.2.154","article-title":"Intake of flavonoids and lung cancer","volume":"92","author":"Le Marchand","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib4","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1021\/jm950938g","article-title":"Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer","volume":"39","author":"Akama","year":"1996","journal-title":"J Med Chem"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/mol.62.1.143","article-title":"Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1\/1A2","volume":"62","author":"Kuffel","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib6","unstructured":"Loaiza-Perez, A.I., Kenney, S., Hollingshead, M., Alley, M.C., Hose, C., Ciolino, H.P. et-al.: Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Unpublished data"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib8","series-title":"Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval","first-page":"101","article-title":"Human tumor xenograft models in NCI drug development","author":"Plowman","year":"1997"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib9","first-page":"51","article-title":"Protocols for screening chemical agents and natural products against animal tumors and other biological systems","volume":"3","author":"Geran","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principles of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib11","series-title":"Statistical Methods, 7th ed","author":"Snedecor","year":"1982"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2174\/1381612023394566","article-title":"Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer","volume":"8","author":"Chen","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib13","first-page":"304","article-title":"P450 enzyme expression patterns in the NCI human tumor cell line panel","volume":"29","author":"Yu","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10408449709021615","article-title":"Aryl hydrocarbon receptor-mediated signal transduction","volume":"27","author":"Rowlands","year":"1997","journal-title":"Crit Rev Toxicol"},{"key":"10.1097\/01.ju.0000108860.03389.1b_bib15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0006-2952(96)00063-9","article-title":"Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists","volume":"51","author":"Lu","year":"1996","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705623919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705623919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1097\/01.ju.0000108860.03389.1b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:16:22Z","timestamp":1651212982000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1097\/01.ju.0000108860.03389.1b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1097\/01.ju.0000108860.03389.1b"],"URL":"https:\/\/doi.org\/10.1097\/01.ju.0000108860.03389.1b","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}